Zymeworks (ZYME) said Monday its phase 3 trial evaluating Ziihera plus chemotherapy as a first-line treatment in gastroesophageal adenocarcinoma showed a statistically significant improvement in progression-free survival compared with trastuzumab and chemotherapy.

Zymeworks said its partner Jazz Pharmaceuticals (JAZZ) plans to submit a biologics license application in H1 2026 as a first-line treatment for HER2+ locally advanced or metastatic gastroesophageal adenocarcinoma.

Shares of Zymeworks surged 29% as intraday trading volume advanced to more than 9.3 million from a daily average of about 737,000.

Shares of Jazz jumped more than 21%, with intraday trading volume at nearly 4.9 million compared with a daily average of about 731,000.

Annovis Bio (ANVS) said Monday that in a phase 3 study in early Parkinson's disease, buntanetap halted cognitive decline across the overall patient population, with the greatest improvement observed in those with mild dementia.

Shares surged 38% as intraday trading volume soared to more than 37.6 million from a daily average of about 627,000.

Price: 24.02, Change: +5.50, Percent Change: +29.70